Untreated AMD worsens vision

Article

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Luis Arias, MD of Bellvitge University Hospital, Barcelona, Spain and colleagues conducted a retrospective, multicentre, epidemiological study of patients referred to retina specialists following a diagnosis of wet AMD.

The researchers found that the median time period elapsing between diagnosis and the first treatment visit was 2.3 months, and the percentage of patients with a VA of 20/400 or worse doubled from diagnosis (12.4%) to initial treatment visit (24.7%). Length of time between diagnosis and treatment showed a high statistically significant correlation to VA degeneration.

The team concluded that substantial VA loss results from untreated wet AMD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.